Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00. According to ...

However, the Goldman Sachs example shows us another ... Firms that succeed at corporate innovation are willing to move slowly to test every element of a business model before investing.

they fared worse on average than in last year’s test. According to a Bank of America report out Thursday, the “worst hit” was Goldman Sachs, with a year-over-year increase of roughly 100 ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...